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Adenocarcinoma of the salivary gland is a histology subtype of salivary gland carcinoma (SGC). Salivary gland
carcinomas are rare tumors accounting for less than 5% of all cancers of the head and neck. Consequently, clinical
data for systemic treatment including targeted treatment in metastatic SGC is limited and supported mainly by
sporadic cases, retrospective reports, and early phase trials with a limited number of patients. We present a case of
a patient who suffered from metastatic SGC, in whom novel molecular testing that uses immunohistochemical
analysis and DNA microarray implied that the tumor would respond to anti-androgen treatment. The patient was
given bicalutamide and achieved complete objective response.
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There are many histology types of salivary gland carcinoma
(SGC), and each subtype has a different growth pattern
and prognosis (Laurie & Licitra 2006). Adenocarcinoma of
the parotid gland indicates that the tumor originates from
the gland (secreting) cells; this is a general term and may
be sub-classified according to morphological properties.
The most common site of distant salivary gland cancer
spread is the lungs. Due to the rarity of this disease, there
is no consensus on the role of systemic chemotherapy and
the optimal treatment regimen in metastatic SGC cases
(Laurie & Licitra 2006). We report a case of metastatic
SGC, using a new molecular technology to identify suitable
drugs targeting this type of tumor.Case report
The patient was a 57-year old female, five years post-
menopausal, without hormone replacement therapy. Past
medical history was positive for hypertension. The patient
was diagnosed with adenocarcinoma of the parotid gland,
for which she underwent total parotidectomy and ipsi-
lateral neck dissection. The pathology report indicated
an adenocarcinoma, 1.4 cm in size, grade 3, with peri-
neural and lymphovascular invasion, and involvement* Correspondence: a_agbarya@rambam.health.gov.il
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in any medium, provided the original work is pof one lymph node adjacent to the parotid gland. Systemic
evaluation included chest computerized tomography (CT)
and bone scan, which demonstrated no evidence of meta-
static disease. The patient received adjuvant radiotherapy
to a total dose of 70 Gy to the tumor bed and involved
lymph node and 50 Gy to the ipsilateral neck.
Ten years later, she presented with respiratory distress
after a trans-Atlantic flight. She underwent CT angiog-
raphy (CTA) to rule out pulmonary emboli. The CTA was
negative for emboli, but showed numerous small, bilateral,
lung nodules (largest diameter 1 cm). The respiratory dis-
tress resolved with conservative and supportive treatment.
Further evaluation with fluorodeoxyglucose positron emis-
sion computed tomography (PET-CT) scan showed an
uptake in her left breast and internal mammary chain,
lung and liver. A biopsy from a lung nodule was positive
for adenocarcinoma similar to the primary parotid gland
tumor. A biopsy from her breast lesion indicated ductal
carcinoma in situ (DCIS). The patient underwent left
lumpectomy and sentinel lymph node dissection. The
pathology report showed DCIS with a focus of invasion.
Adjuvant radiotherapy was applied to her left breast and
then she was started on anti-hormonal treatment using
letrozole as adjuvant treatment. As the patient was asymp-
tomatic and the metastatic disease was slow growing
(according to repeated chest CT scan), it was decided to
continue with letrozole for the breast DCIS, with follow-
up by imaging of the lung lesions.an Open Access article distributed under the terms of the Creative Commons
g/licenses/by/4.0), which permits unrestricted use, distribution, and reproduction
roperly credited.
Figure 1 Negative IHC staining for ER.
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ease. PET-CT showed new uptakes in the mediastinal
lymph nodes, right lung hilus and left mandible. After a
discussion with the patient and a multidisciplinary team, it
was decided to send the histology for a molecular profiling
(MP) analysis. MP was conducted on paraffin-embedded
tissue taken from the 2008 left lumpectomy of a metastatic
lesion. The MP analysis was performed with the Caris Mo-
lecular Intelligence (CMI™) tumor profiling service (Caris
Life Sciences, Irving TX) at the Caris Life Sciences la-
boratories (Phoenix AZ) (Von Hoff et al. 2010). The
analysis included immunohistochemistry (IHC) stainingFigure 2 Focally positive IHC staining for PR.of 10 molecular targets, FISH to identify amplification
in cMET and HER2. RT-PCR was used to determine gene
expression of 12 genes and 6 genes were sequenced by
Sanger sequencing ((EGFR, KRAS, NRAS, C-KIT, PIK3CA
and BRAF). Of the molecular targets analyzed, agents
associated with potential benefit were cisplatin due to
low expression of excision repair cross-complementation
1 (ERCC1) by RT-PCR, taxanes due to high expression of
transducin-like enhancer of split 3 (TLE3) by RT-PCR,
and anti-androgens due to high expression by IHC. The
estrogen receptor (ER) (Figure 1), and progesterone recep-
tor (PR) (Figure 2) status evaluated by IHC were negative
Figure 3 Positive IHC staining for AR.
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gen receptor (AR) (Figure 3) was strongly positive in 90%
of cells with +2 level of staining. Therefore, we decided to
start treatment with bicalutamide 50 mg daily and to con-
tinue the adjuvant treatment of the DCIS with letrozole.
PET-CT after three months indicated a complete response
in the pulmonary nodules (Figures 4 and 5). The patient is
currently 18 months after starting bicalutamide, with no
evidence of progression in her pulmonary nodules origin-
ating from the SGC, while continuing adjuvant treatment
with letrozole for her DCIS for 5 years as acceptable inFigure 4 Pulmonary metastasis from SGC before starting bicalutamidbreast cancer. She will continue treatment with bicaluta-
mide until proof of disease progression.
Discussion
Technological advances have greatly increased our under-
standing of the molecular basis of cancer and treatment
response. It is expected that, as clinicians, we are obligated
to offer such testing in cases where data from large pro-
spective trials is lacking. CMI™ is a novel test that uses im-
munohistochemical analysis and DNA microarray testing
of the tumor. The report offers different treatment optionse.
Figure 5 Complete response in the pulmonary metastasis from SGC, 3 months after starting bicalutamide.
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cific. While the aim is to evaluate the likelihood of benefit
from a specific clinical intervention, it does not necessarily
indicate a clinical benefit. Another limitation is that the
test may offer treatments that are not necessarily included
in guidelines and protocols. The molecular analysis is not
covered under the Israeli National Health Insurance Law
which limits its common use and accessibility. In the case
of salivary gland adenocarcinoma, mostly salivary ductal
carcinomas may show morphological and immunopheno-
typical similarities to ductal carcinoma of the breast and
other glandular structures, such as prostate. In breast can-
cer, IHC-positive cancers for ER and/or HER2 predict
treatment response. Therefore, we speculated that our pa-
tient would respond to anti-androgens.
We previously reported a similar case of aggressive sal-
ivary duct carcinoma (a rare subtype of adenocarcinoma)
that over-expressed HER2 protein and responded to tras-
tuzumab (Kaidar-Person et al. 2012). Androgen receptor
was described in the context of SGC in up to 50% of the
cases, and most originated in the parotid gland (Tarakji &
Kujan 2011; Nasser et al. 2003). Its prevalence was distrib-
uted evenly between genders (Nasser et al. 2003). In the
current case, the patient presented initially with aggressive
features, such as grade 3, perineural invasion, lymphovas-
cular invasion and lymph node involvement; however, it
recurred as a slow growing tumor. The molecular and
genetic analysis performed on the biopsy specimen in-
cluded IHC for ER and PR status, which were negative.
This explains why the SGC tumor progressed under the
breast-specific treatment with letrozole.The expression of receptors, such as HER2 and sex hor-
mones, in some tumors suggests a role for these receptors
in tumor pathogenesis and therapy. SGC that express HER2
has been described as being more aggressive (Glisson
et al. 2004). The prognostic and predictive significance
of these receptors and the clinical efficacy of endocrine
treatment are not confirmed due to lack of data. This
case indicated that this tumor was hormone dependent,
and anti-androgen treatment provided an economical,
well-tolerated treatment option that achieved sustained
complete response on PET-CT.
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